Login / Signup

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.

Ellen BurgessFlorian M M BaeresGeorge BakrisHeidrun Bosch-TrabergMette GislumStephen C L GoughThomas IdornJack LawsonKenneth W MahaffeyJohannes F E MannHenriette MersebachVlado PerkovicKatherine TuttleRichard Pratley
Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to complete in late 2024.
Keyphrases
  • chronic kidney disease
  • end stage renal disease
  • clinical trial
  • electronic health record
  • phase iii
  • machine learning
  • phase ii
  • skeletal muscle
  • weight loss
  • data analysis